. 2022 Feb 23;10(3):346. doi: 10.3390/vaccines10030346

Table 3.

Rotavirus vaccine effectiveness studies conducted in countries with high-mortality stratum.

Ref.	Location	Vaccine	Vaccine Introduction	Study Period	Children Enrolled	Age Eligible Children for VE Analysis	Vaccine Effectiveness for a Completed Series against Rotaviral Admissions of Any Severity: VE% (95% CI)
Ref.	Location	Vaccine	Vaccine Introduction	Study Period	Children Enrolled	Age Eligible Children for VE Analysis	Children < 5 Years	≤12 Months	12–23 Months
[60]	Nicaragua	RotaTeq	October 2006	July 2007–June 2010	11,573	1974	45	64	30
[61]	Bolivia	Rotarix	August 2008	March 2010–June 2011	2545	2318	69	64	72
[62]	Bolivia	Rotarix	August 2008	April 2013–March 2014	870	776	59	76	45
[63]	Guatemala	Rotarix RotaTeq	February 2010	January 2012–August 2013
[64]	Botswana	Rotarix	July 2012	June 2013–April 2015	667	610	54	52	67
[65]	Rwanda	RotaTeq	May 2012	September 2012–May 2015	200	200	75	65	81
[66]	South Africa	Rotarix	August 2009	April 2010–October 2012	2099	1974	57	54	61
[67]	Burkina Faso	RotaTeq	October 2013	December 2013–February 2017	1043	988	35	58	19
[68]	Ghana	Rotarix	April 2012	April 2012–December 2014	1021	657	60	78	50
[69]	Malawi	Rotarix	October 2012	November 2012–June 2015	997	933	58.3	70.6	31.7
[70]	Tanzania	Rotarix	February 2013	March 2013–December 2015	2859	ND	57	56	57
[71]	Zimbabwe	Rotarix	May 2014	June 2014–December 2017	4338	3643	ND	61	−48
[72]	Kenya	Rotarix	July 2014	July 2014–December 2017	677	509	ND	67	72

VE: vaccine effectiveness; CI, confidence interval; ND, no data. VE is calculated for completes series. Only studies with test-negative case-control design are included in this table.